



Redsense signs distribution agreement for the Netherlands with Dirinco BV

Redsense Medical has signed a distribution agreement for the Netherlands with Dirinco that builds upon the letter of intent signed in September 2017. Dirinco offers the Redsense alarm system together with hemodialysis machines from Redsense collaboration partners Nikkiso and NxStage.

"We are excited to have the distribution agreement with Dirinco for the Netherlands in place. They are working with clinics evaluating night dialysis with the Nikkiso DBB-EXA dialysis machine directly connected to the Redsense alarm system for superior patient safety," says Redsense Medicals CEO Patrik Byhmer.

The Netherlands is a large hemodialysis market with nearly 5 000 patients, of which nearly 300 are treated using home dialysis.

Dirinco has over 30 years of experience in offering products to customers on the dialysis market in the Netherlands. The company sells products developed inhouse as well as products from other manufacturers.

For more information, please contact

Patrik Byhmer, CEO Redsense Medical AB (publ)

Telephone: +46 (0) 35 - 10 60 30

Email: patrik.byhmer@redsensemecical.com

Website: www.redsensemecical.com

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. The company has also developed an internationally standardized direct connection enabling compatible dialysis machines to stop the blood flow automatically when blood leakage occurs. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on September 28, 2018.